This segment focuses on developing and commercializing innovative anti-infective solutions to address critical unmet needs in healthcare. The lead product, Mino-Lok, is an antibiotic lock solution designed to salvage infected catheters in patients with catheter-related bloodstream infections (CRBSIs). Research and development efforts are directed towards enhancing the stability and efficacy of Mino-Lok, supported by a robust intellectual property portfolio. The goal is to reduce hospital readmissions, lower healthcare costs, and improve patient outcomes by providing a more effective alternative to catheter removal. Future opportunities include expanding the application of Mino-Lok to other types of indwelling medical devices and exploring new anti-infective agents to combat emerging drug-resistant pathogens.

The Adjunct Cancer Care segment is dedicated to developing therapies that support cancer patients undergoing treatment, focusing on reducing complications and improving quality of life. A key product in this segment is Mino-Wrap, a liquifying gel-based wrap designed to reduce tissue expander infections following breast reconstructive surgeries. Research efforts are focused on optimizing the formulation of Mino-Wrap to enhance its antimicrobial properties and ease of application. By preventing infections, Mino-Wrap aims to minimize the need for additional surgeries, reduce hospital stays, and improve cosmetic outcomes for patients. Future opportunities include expanding the application of Mino-Wrap to other surgical procedures and developing new adjunct therapies to address other common complications of cancer treatment, such as mucositis and neutropenia.

This segment is focused on developing and commercializing prescription products that address prevalent medical conditions and improve patient outcomes. The lead product, Halo-Lido, is a corticosteroid-lidocaine topical formulation intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids. Clinical trials are underway to evaluate the safety and efficacy of Halo-Lido, with a focus on demonstrating superior symptom relief compared to existing treatments. The goal is to provide a convenient and effective option for patients seeking relief from hemorrhoid symptoms, improving their overall quality of life. Future opportunities include expanding the product line to include other topical formulations for dermatological conditions and exploring new delivery methods to enhance drug absorption and efficacy.

The Mesenchymal Stem Cell Therapy segment is dedicated to developing innovative cell-based therapies for the treatment of severe inflammatory conditions. The lead product, NoveCite, is a mesenchymal stem cell therapy being developed for the treatment of acute respiratory disease syndrome (ARDS). Research efforts are focused on optimizing the manufacturing process for NoveCite and conducting preclinical studies to evaluate its safety and efficacy in animal models of ARDS. The goal is to provide a novel therapeutic option for patients with ARDS, reducing lung inflammation and improving respiratory function. Future opportunities include expanding the application of NoveCite to other inflammatory conditions, such as sepsis and autoimmune diseases, and exploring new methods for delivering stem cells to the target tissues.